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Jangkitan daripada virus hepatitis B (HBV) merupakan satu isu kesihatan besar sedunia. 
HBV merupakan suatu faktor terhadap peningkatan risiko  penyakit hepar seperti sirosis 
dan juga dalam perkembangan penyakit kanser hepatosellular. Masalah ini terutamanya 
tersebar luas di rantau Asia-Pasifik, termasuk Malaysia. Semasa jangkitan, e antigen 
hepatitis B (HBeAg) adalah dihasilkan di dalam perumah. Antigen ini adalah satu penanda 
serologi yang penting di dalam diagnosis kesakitan kronik hepatitis B. Perubahan 
(seroconversion) kepada anti-bodi (anti-HBe) merupakan satu faktor terhadap kemajuan 
prognosis pengyakit. Tetapi terdapat beberapa mutasi seperti dwi mutasi  ke atas promoter 
teras (core promoter double mutations) (A1762G1764→T1762A1764), varian kodon 15 (C1858/ 
T1858) dan mutasi pada kodon henti ke atas pra-teras (pre-core stop codon mutation) 
(TGG→TAG) yang boleh memberi kesan kepada pengeluaran HBeAg. Ini boleh 
mengakibatkan implikasi terhadap diagnosis dan klinikal penyakit tersebut. Selain itu, HBV 
juga boleh dibahagikan kepada lapan genotip (A ke H), subjenis genotip dan rekombinan  
juga ditemui. Kajian telah menunjukkan bahawa genotip  berbezaan dari segi hubungan 
dengan mutasi-mutasi tersebut dan juga dengan prognosis penyakit hepatitis B.     
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Infection by hepatitis B virus (HBV) is a major global health-care problem. HBV is an 
accepted factor in the elevated risks for liver disease such as cirrhosis and development of 
hepatocellular carcinoma. This problem is particularly prevalent in the Asia-Pacific region 
which includes Malaysia. During infection, the hepatitis B e antigen (HBeAg) is produced in 
the hosts. This antigen is an important serological marker for diagnosing chronic hepatitis 
B. Seroconversion to anti-body (anti-HBe) corresponds to the improvement of disease 
prognosis. However, certain mutations such as the core promoter dual mutations 
(A1762G1764→T1762A1764), the codon 15 variants (C1858/ T1858) and the precore stop 
codon mutations (TGG→TAG) can affect the HBeAg expression. This has diagnostic and 
clinical implications. Besides that, the HBV can be grouped into eight genotypes (A to H).  
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Moreover, genotypic subtypes and recombinants have been observed as well. Studies 
have observed that these can differ in their affiliations with the mutations above as well as 
with disease prognosis. 
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Hepatitis B virus (HBV) 
 
In 1965, Blumberg and co-workers 
discovered a unique antigen among the 
sera of Australian aborigines (Blumberg et 
al., 1965). They referred to this as the 
“Australian antigen”. Subsequent electron 
microscopy study by Dane et al. (1970) on 
the sera of antigen-positive patients 
revealed vast numbers of spherical and 
filamentous particles of 22 nm in diameter 
and also larger particles of 42 nm in 
diameter with central nucleocapsids and 
outer enveloping coats. With the discovery 
of the 42 nm particles, the term “Dane 
particles” was used. It was shown later that 
the Dane particles were in fact complete 
viral particles and were the causative agent 
for the liver hepatitis. Subsequently, the 
Dane particles were changed to a name 
which we are familiar with today, the 
hepatitis B virus (HBV). The 22 nm 
particles turn out to be the excess non-
infectious surface protein complexes of the 
virus without the nucleocapsid cores. 
 
Molecular background of hepatitis B 
virus (HBV) 
 
Hepatitis B virus (HBV) is a small 
enveloped virus which is 42 nm in 
diameter. Its partially double-stranded DNA 
genome of about 3.2 kb is enclosed by an 
icosahedral structure consisting of 180 or 
240 HBV core proteins (HBcAg) (Bowyer 
and Sim, 2000). Enveloping this structure is 
a coat of lipid bilayer membrane studded 
with the HBV viral surface proteins 
(HBsAg).  
 The genome of HBV is unique in that it 
has overlapping reading frames. Thus it 
can encode about 50 % more polypeptides 
than would be expected from the size of its 
genome (Ganem and Varmus, 1987). The 
compact genome contains four reading 
frames which are the precore/core reading 
frame, preS/ S reading frame, polymerase 
reading frame and the X reading frame 
(Figure 1) (Kidd-Ljunggren et al., 2002). 
The compactness of the HBV genome is 
such that no non-translational region exists 
in it and the regulatory sequences reside 
inside the reading frames themselves 
(Torre and Naoumov, 1998). 
 The precore/core reading frame overlaps 
with the polymerase and X reading frames. 
In this reading frame, two start codons are 
situated, corresponding to the precore and 
core domains of the reading frame. The 
translation from first start codon across 
















Figure 1: Schematic diagram depicting the genome of 
HBV. The negative (-ve) strand DNA is partially 
complemented by its positive (+ve) strand DNA. The 
HBV genomes encode for four reading frames which 
are the polymerase (P), preS/ S reading frame (preS1/ 
-S2/ S), precore/ core reading frame (preCore/ Core) 
and the X reading frame (X). Note the overlapping 
nature of the reading frames.  
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On the other hand, translation of the core 
domain from the second start codon will 
produce the HBcAg. 
 As for the preS/ S reading frame, which 
overlaps with the polymerase reading 
frame as well, three domains exist (namely 
the preS1, preS2 and S domains) with 
three separate start codons defining the 
borders of the respective domains. This 
arrangement permits the preS/ S reading 
frame to produce the HBsAg of three 
different sizes. The largest of these, called 
the L HBsAg, contains the preS1, preS2 
and S domains (Heermann and Gerlich, 
1991). Translation from the second start 
codon will produce a surface protein of 
intermediate size (referred as M HBsAg) 
which contains both the preS2 and the S 
domains. The smallest of the surface 
protein (referred as S HBsAg) consists of 
only the S domain and is translated from 
the third start codon. 
 The other two frames correspond to the 
viral polymerase and X proteins 
respectively, as indicated by the names of 
the reading frames. The polymerase 
reading frame is the largest of all the 
reading frames found in the HBV genome 
and it partially overlaps all the other 
reading frames (Kidd-Ljunggren et al., 
2002). For the viral DNA polymerase, 
besides having the function to replicate the 
viral DNA, other catalytic domains are 
included such as the primase, reverse 
transcriptase and RNase domains (Idilman 
et al, 1998). All of these catalytic domains 
are involved in the vital role of replicating 
the viral genetic material. Briefly, viral 
replication is initiated with the transcription 
of the HBV genome to produce a 3.4 kb 
pregenomic RNA (pgRNA). This RNA 
material is longer than the genome itself 
due to the presence of a redundant short 
terminal (Kidd-Ljunggren et al., 2000). 
 After translation of the viral polymerase, 
the protein will automatically attach itself to 
the 5’-end of the pgRNA. This event will 
initiate the packaging process of the viral 
pgRNA, together with the attached  
 
polymerase, into the nucleocapsid struc-
ture (Wang et al., 1994). This process 
requires the presence of some host factors 
such as the molecular chaperone complex 
of hsp90 (Hu and Seeger, 1996). The viral 
DNA synthesis will occur inside the 
nulecocapsid once packaging is comple-
ted. The primase domain of the viral 
polymerase has a role in initiating the DNA 
replication process through reverse 
transcription where the pgRNA is utilized 
as the template. During the synthesis of the 
minus-strand DNA, the RNase domain of 
the polymerase will degrade the whole 
pgRNA except for a small segment at the 
5’-end. The undigested 5’-end RNA 
segment will function as the primer for the 
subsequent synthesis of the complement-
tary plus-strand DNA. However, before the 
plus-strand DNA synthesis is completed, 
the viral particle will become mature 
through the acquisition of its outer enve-
lope coat consisting of a lipoprotein 
membrane studded with the HBsAg of 
various sizes. This fact explains the 
uniqueness nature of the HBV genome, 
which is partially double-stranded. The viral 
polymerase will remain attached to the viral 
DNA genome, and so be incorporated into 
the viral nucleocapsid as well. Once infec-
tions of the host cells occur, the released 
partially double-stranded HBV genome will 
resume its synthesis of its outstanding 
plusstrand DNA segment, resulting in a 
final complete double-stranded DNA 
genome. 
 Coming to the last polypeptide encoded 
by the HBV genome, HBx is a small protein 
(154 amino acids) which was reported to 
be involved in the modulation of host 
biological processes (Murakami, 1999; 
2001). Some hosts factors that are involved 
in the interactions with the HBx are the 
transcription factors of p53 and Smad4 
(Elmore et al., 1997; Lin et al., 1997; Lee et 
al., 2001). However, there is still much to 
learn about this protein, especially its role 
in the development of hepatocellular 
carcinoma in infected hosts. 
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Epidemiology and pathogenesis of HBV 
 
HBV is one of the most common viral 
pathogen affecting the world population. 
Approximately 350 million people around 
the world are infected with the virus 
(Purcell, 1993). It is estimated that 50 
million new cases are observed annually 
with 5 to 10 % of them being adults while 
the remaining consists of children (Mayerat 
et al., 1999). Infections by HBV can result 
in acute and chronic hepatitis diseases. 
The figure of deaths attributed to HBV 
infection is estimated at 1 million people 
per year (Thomas and Jacyna, 1993). 
Although all body secretions and excretions 
have been found to contain HBsAg, only 
blood, semen, menstrual and vaginal fluids 
have been shown to be infectious 
(Hollinger and Liang, 2001). 
 When infected, the occurrence of liver 
hepatitis is not caused directly by the HBV 
per se but due to the host own immune 
response. When HBV infection occurred, 
the host immune response is stimulated 
where the presence of HBV-specific CD8+ 
cells can be detected in infected subjects. 
As HBV does not directly cause the 
destruction of the hepatocyte it invades, 
the infected hepatocyte acts as a reservoir 
for further infection of other similar host 
cells. This permits the HBV-infected 
hepatocytes to continuously shed the viral 
particles into the blood stream, thus 
ensuring that all the hepatocytes in a 
particular individual are infected (Seeger 
and Mason, 2000). Infected hepatocytes 
will display the immunodominant T cell 
epitopes presented by HLA class I mole-
cules on their surfaces (Chisari and Ferrari, 
1995). This acts as the targets for the 
CD8+ cells to the infected hepatocytes, 
thus resulting in the destruction of the 
infected hepatocytes. 
 Infections by HBV can lead to either 
acute or chronic hepatitis. Acute infection 
usually runs within a period of between 1 to 
6 months, which includes the incubation 
period of between 8 to 20 weeks (Webster 
and Bertoletti, 2002). The clinical symp-
toms that developed following acute 
infection are fever, severe malaise, loss of 
appetite and development of jaundice. 
Most individuals with acute hepatitis B will 
recover with clearance of viral antigens and 
HBV DNA in their sera (Yuen and Lai, 
2001). This is possible when the host 
immune system is strong enough to 
overcome the viral infection. It is believed 
that resolution of the acute hepatitis B 
occurs when adequate productions of B 
and broad-based CD8+ T cells producing 
protective antibodies targeting the epitopes 
of the viral proteins are achieved (Bertoletti 
et al., 1991; Nayersina et al., 1993). 
Besides that, suppression of the viral 
infection is also performed by cytokines 
(especially a and g interferons) and tumor 
necrosis factor (TNF-a) which play a part in 
destruction of the viral replicative inter-
mediates such as viral proteins, the 
replicating DNA and RNA (Tsui et al., 
1995). Individuals who recovered from 
acute hepatitis B will be conferred with life-
long immunity against the virus. However, 
for those who are suffering from acute 
hepatitis B, there is a 1 % chance that the 
conditions for these individuals will dete-
riorate and develop into fulminant hepatitis 
(Lee, 1993). Fulminant hepatitis is cha-
racterized by liver failure which is very 
often fatal. The failure of the liver functions 
is due to sudden massive immune-
mediated lysis of the infected hepatocytes 
without giving enough time for the liver to 
recuperate (Gove and Hughes, 1991; 
Leifeld et al., 2002). A recent study 
speculated that vigorous replication of HBV 
might be a factor involved in the 
development of fulminant hepatitis (Inoue 
et al., 2006). 
 The other form of liver disease that HBV 
infection can lead to is chronic hepatitis B. 
Chronic hepatitis B is characterized by high 
HBV DNA levels, high risk of trans-
missions, elevated liver enzymes such as 
alanine aminotransferase (ALT) in the sera 
and high risk of developing liver cirrhosis 
and liver cancer, hepatocellular carcinoma 
(HCC) (Lok and McMahon, 2001). The 
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activity of viral replication in patients with 
chronic hepatitis B is relatively high where 
it is estimated that 1 x 1011 HBV particles 
are released into the blood circulation 
everyday (Nowak et al., 1996). 
 Chronic hepatitis B could occur when the 
rate of infected liver cells death is balanced 
by HBV infections of new liver cells due to 
the host immune response being not 
vigorous enough to clear the infection. The 
responses of cytotoxic T cells and HLA 
class H restricted T cells against the viral 
nucleocapsid antigens are weak in chronic 
patients (Chisari and Ferrari, 1995). One of 
the contributing factors of chronic hepatitis 
B is the long life-span of hepatocytes with 
an average half-life of 6 to 12 months. The 
stable hostvirus interactions also play a 
role in the persistence of chronic hepatitis 
B. The weak host immune response 
usually leads to scarring, disruption of 
blood flow and obstruction of bile drainage 
of the liver organ, thus interfering with the 
vital liver functions. 
 Given the major role plays by host 
immune system on the development of 
chronic hepatitis B, this liver disease is 
most often incurred by individuals with 
weak immune system. It has been 
estimated that about 90 % of newborns to 
mothers positive for HBeAg will develop 
chronic hepatitis B (Beasley et al., 1983). 
Besides that, about 25 to 30 % of infants 
and children under the age of 5 years old 
will develop chronic hepatitis in their life 
through contacts with persons infected with 
HBV, especially their mothers (Beasley et 
al., 1982; McMahon et al., 1985). New-
borns and young infants are especially 
vulnerable because of the immaturity of 
their immune systems. Besides infants and 
children, immunosuppressed individuals 
such as those infected with HIV-1 or on 
maintenance haemodialysis have a greater 
risk of developing chronic hepatitis B than 
healthy persons when exposed to HBV 
(Bodsworth et al., 1989; Horvath and 
Raffanti, 1994). 
 There is a great chance that chronic 
hepatitis B patients will eventually die from 
liver injuries such as cirrhosis or HCC, 
which is estimated to be about 25 to 40 %. 
Out of these, the fatal rates are 50 % for 
male and 15 % for female (Lau et al., 
1997). It has been estimated that chronic 
hepatitis B patients have a 200 to 300 fold 
of increased risk of developing HCC than 
the general population (Maynard, 1990).  
 In some individuals infected by HBV, no 
discernable symptoms for either acute or 
chronic hepatitis B can be observed. These 
individuals are grouped as the “asymp-
tomatic carriers”. The sera from these 
individuals are positive for HBsAg but have 
normal or minimal raised liver enzymes 
such as ALT (Torbenson and Thomas, 
2002). They can be diagnosed to be 
negative for HBeAg and positive for anti-
HBe with undetectable or low HBV DNA 
level (Lok and McMahon, 2001). Long-term 
follow-up studies showed that 
asymptomatic carriers have lower risk of 
developing liver diseases like cirrhosis or 
HCC and they are less likely to infect other 
individuals (Lindh et al., 2000; Hsu et al., 
2002; Martinot-Peignoux et al., 2002). 
However, about 20 to 30 % of them can 
reacquire hepatitis B disease where 
elevated biochemical indicators, high HBV 
DNA level and sero-reversion from anti-
HBe back to HBeAg can be observed (de 
Franchis et al., 1993; Bellentani et al., 
2002; Hsu et al., 2002). Repeated reactiva-
tions of hepatitis B or a sustained one can 
result in liver injury but frequently symp-
toms may be absent. 
 
Prevalence of HBV infection in Malaysia 
 
HBV infections are endemic in Asia, South 
Pacific, sub-Saharan Africa, Middle East 
and the prevalence are particularly high in 
some indigenous populations such as the 
Aborigines and Native American Indians in 
South and Central Americas (Maynard, 
1990; McMahon, 1997; Mast et al., 1999). 
It is estimated that 75 to 80 % of the HBV 
infection occur in the Western Pacific and 
in the South East Asia regions (Gust, 1996; 
Merican et al., 2000). The high endemicity 
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in these regions is thought to be due to 
mother-to-child perinatal transmission 
(Simmonds, 2001). 
 In Malaysia, one of the earlier studies on 
HBV was performed by Ton et al. (1979). In 
the study, it was found that HBsAg and 
anti-HBc in blood donors from the Kuala 
Lumpur hospital was 5.5 % and 50.1 % 
respectively. When comparison of the 
HBsAg-positivities between the three major 
races in the Malaysian population (Malay, 
Chinese and Indians) was made, no 
significant difference was found between 
them. 
 A study on Malaysian intravenous drug 
users by Mangalam et al. (1986) observed 
that the rate of HBV infections among the 
drug abusers were similar to the general 
population. Thus, this could indicate that 
intravenous drug injections might not be a 
major route of transmission for HBV in 
Malaysia. As in the general case for the 
Asia-Pacific region, the main routes of HBV 
transmission among the Malaysian popu-
lation could be due to mother-to-child peri-
natal transmission as well. 
 In Malaysia, the prevalence of HBV 
infection incidence has been significantly 
reduced since the introduction of a 
nationwide vaccination program in 1989 
(Ng et al., 2005). The program, called the 
Expanded Program of Immunization, invol-
ved three doses of vaccination for the 
newborns. The first dose was given to a 
newborn soon after birth followed by the 
second dose 1 month later and 5 months 
later with the third dose. A particular per-
son is considered to be protected against 
HBV when an anti-HBs titer of at least 10 
mIU/ mL is detected in his or her serum 
(Ng et al., 2005). Prior to the implement-
tation of the vaccination program, a study 
performed by Ton and Noriah (1987) on 
653 healthy Malaysian individuals of both 
sexes revealed that 29.6 % of them were 
positive for the anti-HBs. This is 
comparable to a report on 3807 unvac-
cinated Malaysian school children before 
the program was started where 27.4 % was 
found to be positive for the anti-HBs (Ng et 
al., 2005). After the implementation of the 
program, a statistical analysis on 97786 
school children vaccinated from 1989 to 
1996 showed that 59.3 % of them were 
positive for the anti-HBs and had humoral 
immunity against HBV (Ng et al., 2005). 
The successful result of this vaccination 
program saw a reduction from 2.7 % to 0.4 
% of HBsAg carriers among school children 
during the study period. 
 However, despite the implementation of 
the vaccination program, a significant 
proportion of the Malaysian population is 
still afflicted with HBV. Merican et al. (2000) 
reported that about 75.3 % of the chronic 
hepatitis diseases suffered by patients is 
caused by HBV. A study on 17048 healthy 
Malaysian volunteers (mean age, 34 years) 
found that 893 were positive for HBsAg 
(Merican, 1999). Taking this study as a 
representative figure of the current HBV 
infection in the Malaysian population, it is 
estimated that about 5.24 % are struck 
down with chronic hepatitis B. When 
stratified according to the ethnic 
composition of the Malaysian population, 
the Chinese incurred the highest proportion 
of HBV infections, followed by the Malays 
and Indians (Yap, 1994; Merican et al., 
2000). When compared with the study 
done by Ton et al. in 1979, it can be 
observed that the current level of the Ma-
laysian population positive for HBsAg is 
comparable to that found in a sample 
population of more than 20 years ago. 
However, it seems that the demography of 
infection between the different races has 
changed since the study was performed in 
1979. 
 The infections by HBV in Malaysia have 
created a major healthcare problem as 
acute and chronic hepatitis B patients 
require substantial medical attention. In a 
study to determine the causes of jaundiced 
cases surveyed among patients admitted 
into the hospitals in Kelantan and 
Terengganu in 1996, Saat et al. (1999) 
found that 1.4 % of the cases could be 
traced to infection by HBV. Due to their 
frequent close proximity with HBV carriers, 
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health care workers are at an increased 
risk to exposure to HBV. A study among 
the health care workers in Negeri Sembilan 
in 1989 observed that a substantial number 
of the health care workers were positive for 
the serological markers for HBV (Tan et al., 
1992). The study involved 2500 health-care 
workers of which about 25 % were found to 
be positive for the serological markers. 
Further stratification revealed that 2.1 % 
had HBsAg while 22.8 % were positive for 
anti-HBs. However, for the latter cases, it 
was not known whether the positivity for 
anti-HBs was due to history of HBV 
infection or to vaccination. Given this 
situation, it is imperative that steps should 
be taken to vaccinate the health-care 
workers in order to offer them protection 
against HBV. In lieu of this, the Universal 
Precautions Policy guidelines were 
adopted for health care workers. To find 
out if the policy was properly implemented, 
a survey on the protective status against 
HBV was performed on 625 subjects 
comprising health-care workers and under-
graduate students undergoing clinical 
training in two hospitals in Kuala Lumpur in 
2001 (Hesham et al., 2005). It was ob-
served that only 58.4 % of the subjects had 
taken a complete HBV vaccination course 
while 82.2 % of the subjects had only been 
vaccinated with a single dose. HBV 
infections could also increase the burden 
faced by the current health-care system. 
HBV-contaminated blood could cause in-
fections among patients seeking treatment 
for other types of illnesses. For example, in 
a report by Menon and Aiyar (1997), it was 
mentioned that about 20% of the 55 
paediatric oncology patients who received 
blood products at Hospital Universiti Sains 
Malaysia in Kota Baru were positive for 
HBsAg. Besides that, the treatment costs 
for HBV infections are expensive. The 
current regime of anti-viral treatments 
administered for patients infected with HBV 
in Malaysia are the a-interferon, lamivudine 
and thymosin a-1 (Mohamed et al., 2004). 
Besides it was observed that about 80 % of 
the HCC cases observed in the country 
were caused by HBV (Yap, 1994). 
 
HBeAg / anti-HBe productions and the 
associated mutations 
 
HBeAg is a viral protein that does not form 
a part of the structure of the viral particles 
but shares about 90 % of the amino acid 
sequence with the HBcAg. This is because 
the HBeAg is translated from the first start 
codon of the precore/ core reading frame, 
resulting in larger precursor protein of 
HBeAg with an extra N-terminal domain of 
29 amino acid residues. The first 19 amino 
acid residues of the extra N-terminal 
functions as a signal peptide to guide the 
precursor HBeAg to the host endoplasmic 
reticulum compartment to be processed. 
Processing of this immature protein in the 
endoplasmic reticulum will result in the 
cleavage of the 19 residues from the 
precursor HBeAg. Subsequently, the C-
terminal domain will be cleaved off as well 
at the arginine-rich region, thus resulting in 
a shortened mature form of HBeAg which 
is then secreted out from the host cells 
(Lau and Wright, 1993). Some of the 
mature HBeAg is localized on the host cell 
membrane while the rest is secreted into 
the blood stream. In comparison, the 
HBcAg does not have the N-terminal 
domain and retains its C-terminal domain. 
Despite the high similarity between these 
two viral proteins, their tertiary structural 
conformations are quite different. This is 
due to the presence of an intramolecular 
disulfide bond in the HBeAg (Nassal and 
Rieger, 1993; Wasenauer et al., 1993). 
 HBeAg is utilized as a serological marker 
for the infectivity of HBV, in particular 
individuals, in clinical diagnosis (Magnius 
and Espmark, 1972; Shikata et al., 1977). 
HBeAg is usually detected in the serum 
when HBsAg begins to appear. The 
presence of HBeAg in the serum correlates 
with the presence of viral activity in the 
liver. In the diagnosis of acute hepatitis, 
HBeAg does not play an important role as  
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a diagnostic marker because the antigens 
are cleared within weeks after the acute 
disease has resolved. However, in chronic 
hepatitis B, this antigen is important as an 
indicative marker as HBeAg can remain 
detectable for a sustained period of time, 
usually in terms of months or years 
(Merican et al., 2000). 
 The function of HBeAg with respect to 
the virus is not fully understood yet. In an in 
vitro study, the absence of HBeAg does not 
seem to impede replicative ability of the 
virus (Tong et al., 1991). It is speculated 
that HBeAg might play a role in tricking the 
immune defense system of the infected 
host. It has been proposed that the expres-
sion of HBeAg during perinatal infection 
can induce immune tolerance of the HBV 
by the host and that the HBeAg acts as a 
buffer to attack by anti-HBc on infected 
hepatocytes. This reasoning is based on 
the high sequence similarity between 
HBeAg and HBcAg (Tong et al., 2005). 
 Nevertheless, HBeAg positivity in HBV-
infected patients has been found to be one 
of the risk factor for the development of 
liver cirrhosis (Liaw et al., 1988; Realdi et 
al., 1994; Yu et al., 1997). In cirrhotic 
patients, the presence of HBeAg is one of 
the risk factors in the occurrence of liver 
decomposition (Fattovich et al., 1995). It 
was reported that patients with decom-
pensated cirrhosis who were negative for 
HBeAg have a better 5 year survival rate 
than those who were positive for the 
antigens (de Jongh et al., 1992). A reduce-
tion in the risk of developing hepatic 
decompensation and survival improvement 
can be achieved after the clearance of 
HBeAg, either spontaneously or after 
undergoing anti-viral treatments (de Jongh 
et al., 1992). 
 With the disappearance of HBeAg from 
the serum, seroconversion to anti-HBe can 
occur. The presence of anti-HBe in the 
early phase of acute hepatitis is an 
indication of the resolution of the acute 
infection. On the other hand, in chronic 
hepatitis B, the disappearance of HBeAg 
and appearance of anti-HBe is associated 
with improved biochemical and histological 
standing of the liver disease. 
 Although anti-HBe positivity in HBV-
infected patients signifies clinical im-
provement, in some cases liver damage 
may still persist with active HBV DNA 
replication (Hadziyannis, 1995). Even after 
seroconversion to anti-HBe, reactivation of 
viral replication can still occur where 
seroreversion back to HBeAg positive 
status can happen. 
 Besides that, mutations in the HBV 
genome affecting HBeAg productions can 
also result in the emergence of HBeAg-
negative mutants. Two of the most pro-
minent mutations in these HBeAg-negative 
mutants are the A1762G1764→ 
T1762A1764 core promoter mutations and 
the precore stop codon mutation. The 
A1762G1764→T1762A1764 dual muta-
tions occur in the core promoter region that 
regulates the transcription of both the 
precore-mRNA, which is the template for 
HBeAg and the pgRNA (Figure 2) (Yuh et 
al., 1992; Takahashi et al., 1995). The 
precore stop codon mutant is characterized 
by a G to A nonsense nucleotide mutation 
at nucleotide 1896 of codon 28 of the 
HBeAg (TGG→TAG) which can result in 
the truncating of the translation of HBeAg 
into a short peptide of 28 amino acids 
(Figure 3) (Brunetto et al., 1989; Carman et 
al., 1989; Tong et al., 1990). 
 Besides these two mutations, the base 
variants at nucleotide 1858 in codon 15 
can affect HBeAg production as well. The 
common variants exist at the aforemen-
tioned site are the C1858/ T1858 variants. 
These variants are not directly involved in 
the truncation of the HBeAg production per 
se as conversion from one variant to the 
other will result in a silent mutation. 
However, they affect the HBeAg production 
through their pairing to nucleotide 1896 of 
the codon 28 in the secondary loop 
structure of the pgRNA (Figure 3). This 
loop is a hair-pin structure which functions 
as an encapsidation signal. This structure 
is essential for recruitment of the HBV 
polymerase which in turn is essential for  
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Figure 2 : The dual mutations of A1762G1764→T1762A1764 at the core promoter region preceding the preCore/ 



























Figure 3 : The encapsidation signal structures of the pgRNA and the bases pairing between the C1858/ T1858 
variants at nucleotide positions 1858 and 1896. (a) Although pairing of uracil (nt 1858) and guanine (nt 1896) are 
not compatible, this pairing is permitted due to the wobble pairing nature between the bases, thus conserving the 
essential stem loop structure of the encapsidation signal. (b) The compatible pairing between cytosine (nt 1858) 
and guanine (nt 1896) will permit for the conservation of the encapsidation signal structure. (c) Pairing between 
uracil (nt 1858) and adenine (nt 1896) is compatible. This compatibility will allow for the stable mutation of G to A 
at nt 1896, thus preserving the precore stop codon mutation (TGG→TAG). (d) The incompatible paring between 
cytosine (nt 1858) with adenine (nt 1896) will result in the disruption of the encapsidation signal structure. 
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(2002) had also performed sequencing  
analyses on the HBeAg-negative samples 
which were not infected by the mutants. 
The sequencing analyses revealed that 5 
of them had the A1762G1764→ 
T1762A1764 dual mutations while another 
sample had mutation at the start codon. On 
top of that, they found a significant 
association between T1858 variants with 
the precore stop codon mutations, which 
concurs with many other studies. 
the synthesis of the HBV genome and viral 
replication. Disruption of this structure is 
detrimental to the HBV replication. In the 
hair-pin secondary structure of the 
encapsidation signal, the nucleotide at 
1858 is intimately paired to nucleotide 1896 
through base pair bonding. Thus, the fate 
of precore stop codon mutation 
(TGG→TAG) is dependent upon the 
nucleotide at 1858. When cytosine is the 
nucleotide in place at nucleotide 1858 
(hence referred as the C1858 variant), 
stable formation of the precore stop codon 
mutant will be prevented (Figure 3). This is 
due to the reason that incompatible pairing 
of adenine at 1896 with cytosine at 
nucleotide 1858 will confer a weak binding 
force to the encapsidation signal structure. 
 In another study conducted in Malaysia, 
it was observed that among the sera 
samples from 44 HBV-infected patients, 
the prevalence of the core promoter 
mutations and precore stop codon muta-
tions were determined to be 56.8 % and 
9.1 % respectively (Ton et al., 2002). 
Intriguingly, in their study, it was observed 
that the number of patients with HBeAg-
positive status was higher than those with 
anti-HBe-positive status when those in-
fected with the core promoter mutants were 
taken into account. In comparison to a 
study on Brazilian HBV carriers with anti-
HBe positive status, only about 24 % of 
them were found to be infected with the 
precore stop codon mutations (Castro et 
al., 2001). They reasoned that this was due 
to the large majority of the subjects being 
infected by the C1858 variants which, as 
discussed above, would preclude the stop 
codon mutation.  
 This will cause a disruption to the all 
important structure and so prohibiting the 
replication of the HBV mutant. On the other 
hand, if the nucleotide at 1858 is a thymine 
(hence referred as the T1858 variant), the 
formation of the precore stop codon mutant 
is conducive as the thymine can stably 
pairs with adenine at nucleotide 1896. 
Besides that, TGG wild-type can exist as 
well because the thymine at 1858 can 
wobble pair with guanine at nucleotide 
1896 without disrupting the essential 
encapsidation signal structure (Lok et al., 
1994). 
 In Malaysia, an early study performed by 
Ton et al. (1996) on 43 HBsAg Malaysian 
carriers showed that infections by the 
C1858 variants were quite substantial. In 
the study, 4 of the 43 samples (9.3 %) 
were found to be of precore stop codon 
mutants. Of interest was that two of the 
mutants were found to co-exist with the 
TGG wild-type. In another study, Yap et al. 
(2002) detected 13 precore stop codon 
mutants out of 33 HBeAg-positive and 32 
mutants out of 48 HBeAg-negative 
Malaysians sampled. In comparison to a 
study outside the country, Okamoto et al. 
(1994) observed a staggering high 
frequency of about 90 % of the mutants in 
patients positive to anti-HBe. Yap et al.  
 
 However, in a later study on HBV-
infected Malaysian patients, only low 
numbers of the above mutants were 
observed (Lim et al., 2006). In the study, 
only 11 out of 77 (14.3 %) HBV-infected 
patients examined were found to be 
infected with the core promoter mutants 
while 7 (9.1 %) were co-infected by both 
wild-type and the mutants. Interestingly, no 
significant correlation was observed 
between the core promoter mutations and 
the HBeAg/ anti-HBe status in this study. 
This contradicts with a few other studies in 
other part of the world where such 
correlations were observed (Hussain et al., 
2003; Okamoto et al., 1994). Despite this 
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anomaly, many other studies did not 
observe such correlations (França et al., 
2004; Lindh et al., 1999, Orito et al., 2001, 
Takahashi et al., 1995). One possible 
explanation for this is that the occurrences 
of T1762A1764 mutations only decrease 
the productive capability of HBeAg of the 
particular HBV strain but not totally 
abolishing it. It was shown by Parekh et al. 
(2003) that T1762A1764 mutations could 
only reduce the HBeAg production by 
about 20 %. 
 Of interest is the observations of sera 
which were positive for both HBeAg and 
anti-HBe in two of the sera samples in the 
Malaysian study (Lim et al., 2006). This 
was also encountered in an earlier study by 
Ton et al. (1995) on sera taken from some 
Malaysians infected with HBV. The status 
of positivities for both HBeAg and anti-HBe 
might signify the ongoing process of sero-
conversion whereby the HBeAg serological 
marker was not completely eliminated from 
the blood circulation yet. 
 Also, in the study by Lim et al. (2006), no 
precore stop codon mutations were 
observed among the HBV samples 
examined. The study also showed that of 
the 46 samples that were successfully 
assayed, 33 of them were infected by the 
T1858 variants while 13 were infected by 
the C1858 variants. This was in 
concordance to an earlier study by Ton et 
al. (2001) where the occurrences of the 
T1858 variants significantly predominate 
over the C1858 variants (82.1 % vs. 14.8 
%). 
 Due to the lack of any precore stop 
codon mutant in the study by Lim et al. 
(2006), no correlation study between 
T1858/ C1858 variants of codon 15 with 
nucleotide 1896 of codon 28 was 
performed. However, co-infections of the 
precore stop codon mutants and the wild-
type strains could still be observed among 
the Malaysian HBV carriers (Ton et al., 
2001). The contrasting results observed 
between the various studies conducted in 
Malaysia could indicate that the distribution 
of the HBV mutants among the Malaysian 
population is not permanent but varies in 
time as well as in locations. 
 Other than the core promoter mutations 
and the precore stop codon mutations, 
there are other less well-known mutations 
which could reduce the production rate of 
HBeAg. It was shown by Parekh et al. 
(2003) that, in combination with the 
T1762A1764 mutations, mutations at 
nucleotides 1753 and 1766 could result in 
a decrease in HBeAg production by up to 
80 %. Besides that, some mutations 
occurring downstream of the precore start 
codon can decrease HBeAg translation too 
(Ahn et al., 2003). In addition to these, 
mutations such as at the precore start 
codon or TAA stop codon mutation at 
codon 2 could also abolish the production 
of HBeAg (Lindh et al., 1996). These 
mutations could explain for the presence of 
HBV in anti-HBe-positive patients where 
both the core promoter and the precore 
stop codon mutations were not detected. 
 
Association of mutations affecting 
HBeAg productions with liver disease 
prognosis 
 
Although the mutations mentioned 
previously are associated specifically with 
HBeAg productions, many studies found 
that they could be related to the prognosis 
of liver diseases as well. The 
A1762G1764→T1762A1764 dual muta-
tions were frequently observed in patients 
with chronic hepatitis but were rarely found 
in asymptomatic carriers (Okamoto et al., 
1994; Kim et al., 1999). These mutations 
were also associated with increased 
inflammation and fibrosis in both HBeAg-
positive and HBeAg-negative HBV infected 
chronic hepatitis patients (Lindh et al., 
1999). The mutations had also been found 
to be associated with fulminant hepatitis in 
a few studies (Sato et al., 1995; Friedt et 
al., 1999). These mutations do not affect 
the transcription of HBV pgRNA from which 
the viral core peptides are translated 
(Okamoto et al., 1994). With the occur-
rences of these mutations, the equilibrium 
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balance between HBeAg in the blood 
circulation and the core peptides presented 
by the class 1 HLA molecules on the sur-
face of infected hepatocytes will be 
eliminated. As HBeAg has been shown to 
have suppressive effect on T helper cells, 
its down-regulation may explain the asso-
ciated clinical prognosis observed. The 
core peptide has been determined to 
contain most of the primary sequence of 
HBeAg. Thus, it is possible that circulating 
HBeAg may prevent cytotoxic T lympho-
cytes from recognizing infected 
hepatocytes which display the core 
peptides on their surface by their HLA 
molecules. This is significant because 
cytotoxic T lymphocytes may be directed to 
the infected hepatocytes that display the 
core-derived peptides and so causing 
injury to them (Mondelli et al., 1982; 
Bertoletti et al., 1991). The decreased 
synthesis of HBeAg could free some of the 
cytotoxic T lymphocytes from their 
suppressive effect and so a greater 
number of the lymphocytes may be 
directed toward the infected hepatocytes 
thus resulting in greater liver injury 
(Takahashi et al., 1995). One study has 
shown that HBcAg is able to activate a 
more vigorous immune response than 
HBeAg in vivo, thus causing more severe 
liver damage (Nishizono et al., 1997). 
 As mentioned, the disruption of HBeAg 
production could result in the withdrawal of 
hepatocyte display of HBeAg-derived cyto-
toxic CD8+ T cell epitopes but viral 
replication will not be affected (Carman et 
al., 1993). In a study by Yuasa et al. 
(2000), it was found that most Vietnamese 
patients with fulminant hepatitis carried the 
precore stop mutation while none was 
found in patients with acute non-fulminant 
hepatitis. This is in concordance to an 
earlier study where similar observation was 
made (Omata et al., 1991). Transmission 
of these HBV mutants may lead to 
development of fulminant hepatitis in the 
newly-infected individuals (Yotsumoto et 
al., 1992; Liang et al., 1994). Besides, 
mutation in codon 28 could render the HBV 
strain with enhanced encapsidation advan-
tage that makes them more infectious and 
causes hepatitis when they do so 
(Scaglioni et al., 1997). 
 Lai et al. (1994) reported that mutations 
at codon 28 were associated with most 
anti-HBe seroconversion. Generally, the 
occurrences of mutations at the precore 
stop codon before seroconversion appear 
to shorten the time of onset of sero-
conversion (Brunetto et al., 1991). It was 
found to be correlated with persistence 
viral detection in the blood circulation and 
increased ALT levels for at least 6 months 
after seroconversion (Brunetto et al., 
1991). It was also found to be correlated 
with elevated frequency of cirrhosis 
development in patients (Brunetto et al., 
1991). These show that the timing of the 
emergence of the mutation could have 
clinical implications on affected patients. 
Besides, Marusawa et al. (2000) found that 
the predominance of TAG mutation after 
seroconversion correlated with increased 
liver injury. The precore stop codon 
mutations were also associated with 
severe recurrent HBV infection after liver 
transplantation (Angus et al., 1995). 
 This mutation has also been associated 
with increased susceptibility to coinfection 
by hepatitis D virus (HDV) (Raimondo et 
al., 1991). Hepatitis D virus is a satellite 
virus of HBV. This virus can only replicate 
in the hepatocytes that are infected by 
HBV. This is because HDV requires the 
proteins that are expressed by HBV in 
order to form its own nucleocapsid and has 
its own RNA genome packaged. 
 Lindh et al. (1996) observed that carriers 
infected with the C1858 variants showed 
more liver damage than carriers infected 
with the T1858 variants. They suggested 
that carriers with the C1858 variants might 
remain longer in the HBeAg-positive phase 
or maintain some HBeAg production 
capabilities even after seroconversion to 
anti-HBe. They hypothesized that the 
HBeAg is a target for the necroinflam-
matory process, thus causing more severe 
liver injury. However, patients infected with 
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the C1858 variants responded better to 
interferon therapy than those infected with 
the T1858 variants (Zhang et al., 1996). In 
Malaysia, Ton et al. (2001) observed that 
many of the asymptomatic carriers and 
patients with HCC were infected with this 
T1858 variant than in those suffering from 
chronic hepatitis. 
 Further, many studies found that 
simultaneous occurrences of the precore 
stop codon mutations and the core 
promoter mutations would result in more 
severe cases of liver injury (Brunetto et al., 
1991; 1993; Laskus et al., 1998; Inoue et 
al., 1998; Honda et al., 1999). 
 Although a lot of studies point toward the 
association of the above mutations with 
increased risks of liver injuries, many other 
studies did not find such correlations. 
Castro et al. (2001) demonstrated that the 
core promoter mutations were not linked to 
increased liver injuries. In the case of the 
C1858/ T1858 variants, no significant 
clinical differences were observed between 
patients infected by these two variants 
(Sakurai et al., 2004). Similarly, the issue 
of increased risk of liver injury associated 
with infection by HBV strains with 
simultaneous precore stop codon 
mutations and the core promoter mutations 
is not resolved yet as many other studies 
refute this claim (Okamoto et al., 1990; Hsu 
et al., 1995; Lindh et al., 1996; Pollicino et 
al., 1995). 
sequences of the S gene by Norder et al. 
(1993). Genotype G was discovered by 
Stuyver et al. (2000) from HBV carriers in 
France and blood donors in the United 
States of America. They reported that this 
genotype has a minimum divergence of 
11.7 % (genotype G versus E) and a 
maximum divergence of 15.3 % (genotype 
G versus genotype H) when compared with 
other genotypes over the whole genomes. 
This genotype is unique in that it has a 
nucleotide insertion of 36 bp, situated after 
the fifth nucleotide after the core translation 
initiation point (nucleotide 1901) (Stuyer et 
al., 2000). The latest addition to the family 
is the genotype H which was observed 
from HBV-infected patients in Central 
America (Arauz-Ruiz et al., 2002). 
 
Geographic distribution of HBV 
genotypes 
 
The prevalence of the HBV genotypes can 
be localized into different geographic 
areas. Genotype A has been found to be 
predominant in Northern Europe and North 
America while genotype D is predominantly 
found in the Mediterranean region 
(Magnius and Norder, 1995). In Asia, 
genotype A can be found in high frequency 
in India, Indonesia and the Philippines (Huy 
and Abe, 2004). Genotypes B and C are 
found predominantly in the Far East such 
as China, Japan and the South-East Asia 
region (Magnius and Norder, 1995). There 
is a tendency for genotype C to have 
higher prevalence in Northern mainland 
China and in Japan than genotype B (Orito 
et al., 2001). Genotype E is found mainly in 
parts of East, Central and West Africa. As 
for genotype F, it is found mainly in South 
and Central Americas as well as in some 
Pacific islands such as the Polynesia. So 
far, genotype G has been observed in the 
United States of America, Germany and 
France and could be found in Mexico as 
well (Stuyer et al., 2000; Vieth et al., 2002; 
Sanchez et al., 2002). As mentioned 




 The genotype system of HBV was first 
proposed by Okamoto et al. (1988) with an 
initial of 4 genotypic groups (i.e. A to D) 
classified, being distinguished based on an 
inter-genotypic divergence of 8.5 to 10.0 % 
between 18 complete HBV genomes and 
with a divergence of 1.1 to 2.7 % between 
isolates within the same genotype. The 
genotype classification was later extended 
to 6 genotypic groups (genotypes A to F), 
with addition of genotypes E and F, 
through phylogenetic analysis on 122  
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localized to the Central America region. 
 In the Malaysian context, a small study 
performed by Ong et al. (2005) through 
sequencing on the pre-S and S regions of 
the HBV genome extracted from sera of 
HBV infected Malaysian carriers revealed 
that the genotypes B and C were the most 
prevalent strains. This was confirmed in 
later study on a larger Malaysian 
population sample where the prevalence of 
genotype B was to be highest (56.9 %) 
followed by genotype C (31.4 %) (Lim et 
al., 2006). 
 
Co-infections by several genotypes 
 
Besides single genotypic infections, 
simultaneous infections by two different 
HBV genotypic strains are possible. These 
events can occur in countries where 
endemicity of several genotypic strains of 
HBV is prevalent. One of the first evidence 
of co-infections by two different genotypes 
was reported by Kao et al. (2001). In their 
large study, the frequency of co-infections 
by genotypes B and C was found to be 0.8 
%. Since then, other studies had revealed 
that co-infections could be quite common, 
with a rate of co-infections of between 4.4 
to 17.5 % (Ding et al., 2003; Kato et al., 
2003, Osiowy and Giles, 2003; Chen et al., 
2004; Olinger et al., 2006). In the local 
setting, a study on Malaysian HBV carriers 
revealed that 7.8 % of the sample 
population studied was coinfected by 
genotypes B and C (Lim et al., 2006). 
 Even more intriguing is the report of triple 
simultaneous infections by three different 
genotypic strains (Chen et al., 2004). The 
report stated that in a group of intravenous 
drug users infected by HBV, 0.9 % of them 
had triple infections by the genotypic 
strains of A, B and C. 
 
HBV genotypic subtypes 
 
The main genotypes can be further divided 
into subtypes. These had been determined 
in a few studies based on phylogenetic 
analysis (Norder et al., 1994; Bowyer et al.,  
1997; Bowyer and Sim, 2000; Mbayed et 
al., 2001). It was found that genotype C 
could be further subdivided into subtypes 
with genotype C adrq serotype being more 
common in the Pacific islands than in 
South-East Asia (Norder et al., 1993). 
Norder et al. (1994) showed that Cq- 
subtype of genotype C in the Pacific region 
also differed from subtypes found in the 
Asia region. A study by Lindh et al. (1997) 
using the PCR-RFLP on the S region 
showed that within genotype C, RFLP 
pattern C1 was present in all Northeast 
Asian carriers while South-East Asian 
carriers had another RFLP pattern, 
designated as C2. Furthermore, a later 
study has found that the genotype C can 
be subdivided into the subtypes Ce and Cs 
(Chan et al., 2005). 
 A study performed on the urban 
population of South Africa by Bowyer et al. 
(1997) showed that there exists two 
subtypes for genotype A, designated as 
subtypes A and A’. Mbayed et al. (2001) 
found the existence of four clusters of 
subtypes within genotype F which were 
associated with different geographical 
locations. Esteban et al. (1999) theorized 
that HBV genotypic subtypes were likely to 
evolve in different ethnic backgrounds over 
the centuries of HBV infections. 
 In a study by Sugauchi et al. (2003), two 
distinct subtypes of genotype B were 
found, namely Bj and Ba. The main 
difference between these two subtypes is 
that the genome of Ba subtype has 
undergone recombination with the 
genotype C over the regions of the precore 
and core gene while in Bj, no such 
recombination occurred. In Japan, the Bj 
subtype is the dominant strain while Ba is 
found mainly in other Asian countries such 
as China, Hong Kong, Taiwan, Thailand 
and Vietnam. 
 As more and more studies are conducted 
in this area, it is expected that more 
genotypic subtypes will be discovered. The 
consensus for distinguishing between 
genotypic subtypes now stands at 4% 
(Kramvis and Kew, 2005). A total of at least 
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authors suggested that these could be due 
to recombinatorial events between the 
genomes of different genotypes (Hannoun 
et al., 2000; Owiredu et al., 2001). It is 
postulated that this phenomenon occurs in 
an environment when co-infections by 
several genotypes exists. HBV has a high 
replicative capability where up to 1013 viral 
particles can be produced everyday as well 
as high mutation rate due to the absence of 
proof-reading capability on the part of the 
viral polymerase (Nowak et al., 1996; 
Brechtbuehl et al., 2001). This leads to a 
proposal by Schaefer (2007) which states 
that the existence of such hybrids is a 
result of rapid adaptation of the HBV to 
new host immunological selections 
encountered in different human 
populations. Another more sophisticated 
theory on the occurrence of such hybrids is 
the theory of HBV genome mosaicism 
(Bowyer and Sim, 2000). This theory 
suggests that the existence of HBV 
genotypes are due to the modular 
construction of the HBV genome from 
different small segments of HBV genomes 
of various genotypes (Bowyer and Sim, 
2000; Simmonds and Midgley, 2005). It is 
supported by a discovery of the activation 
or repression of the preCore-pregenomic 
promoter (enhancer II) by the transcription 
factor COUP-TF which is genotype-
dependent (Fischer et al., 2006). 
24 genotypic subtypes have been identified 
so far (Schaefer, 2007). 
 It remains to be established whether the 
HBV strains of genotypes B and C infecting 
Malaysians are of the subtypes Ba or Bj in 
the case for genotype B and of subtypes 
Ce or Cs for genotype C or it could be 
some other undiscovered subtype alto-
gether. 
 
Recombinant hybrids of different 
genotypes 
 
In certain situations, recombinations 
between HBV genomes of different 
genotypic strains were reported. As 
discussed earlier, one of this is the 
genotypic subtype Ba, which is a result of 
recombination between HBV genomes of 
genotypes B and C (Sugauchi et al., 2003). 
From the current literature, the majority of 
the recombinant hybrids observed are of 
genotypes B/ C and A/ D (Simmonds and 
Midgley, 2005; Yang et al., 2006). Other 
recombination hybrids that have been 
discovered are A/ B/ C, A/ C, A/ E, A/ G, C/ 
D, C/ F and C/ G (Schaefer, 2007). In 
some regions, the recombinant hybrids are 
the predominant HBV strain infecting the 
local population. In Tibet for example, it 
was observed that the recombinant hybrid 
of genotypes C/ D was the most prevalent 
strain detected (Cui et al., 2002; Wang et 
al, 2005; Zeng et al., 2005). Whether such 
hybrids exist among the Malaysian local 
HBV strains remain to be seen. 
 
The associations of HBV genotypes 
with clinical prognosis 
  From the various studies, it was 
observed that there is a tendency for the 
recombinatorial breakpoints to cluster at 
certain regions of the HBV genome. Some 
of these recombination breakpoints which 
commonly occur are at the preS1/ 2 region 
(nt 3150-100), the 3’-end region of the 
Core gene (nucleotide 2330-2450) as well 
as at the 3’-end region of the Surface gene 
(nt 650-830) (Simmonds and Midgley, 
2005; Yang et al., 2006). 
Studies have shown that HBV genotypes 
correlated to different degree of severity of 
liver diseases. Kao et al. (2000a) observed 
that HBV genotype C associated more with 
severe liver disease while genotype B was 
associated with the development of HCC in 
young HBsAg-positive carriers. A further 
study revealed that patients with genotype 
C infections had slightly higher sera HBV 
DNA levels and significantly higher ALT 
levels than patients infected with genotype 
B (Kao et al., 2000b). Besides individuals 
 However, the mechanism in which these 
events occur is still not clear. Some  
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infected with genotype B would undergo 
HBeAg seroconversion to anti-HBe at a 
younger age (Chu and Lok, 2002; Kao et 
al., 2002; Sumi et al., 2003). 
 On the other hand, genotype A was 
found to be present in higher frequency in 
chronic hepatitis patients than in acute 
patients (Mayerat et al., 1999). In a study 
performed by Kobayashi et al. (2002a), 
they found that chronic hepatitis tend to 
occur more frequently in patients infected 
by genotype A than by genotypes B or C. 
Cases had also been reported where acute 
infections by HBV genotype A evolved 
more frequently into chronic infection 
(Kikuchi et al., 1998; Niitsuma et al., 1999). 
These findings could lead to the reasoning 
that in Western countries, where genotype 
A infections are prevalent, there is a high 
rate of chronic infection after HBV infection 
during adulthood (Sherlock et al., 1987; 
Heijtink et al., 1999; Lindh et al., 2000). 
Furthermore, Kobayashi et al. (2002b) 
showed that patients infected with HBV 
genotype A had higher HBeAg levels than  
those infected by genotypes B or C. 
 In the Indian sub-continent, genotype D 
was more associated with severe forms of 
liver diseases than genotype A (Thakur et 
al., 2002) and that patients below the age 
of 40 years old had higher incidence of 
getting HCC when infected by genotype D 
than by genotype A. Mayerat et al. (1999) 
suggested that HBV genotype A has lower 
antigenicity than genotype D, thus it is less 
capable of inducing the immune clearance 
phase and so lead to a higher incidence of 
chronic hepatitis. In the Mediterranean 
region, infection by genotype D was 
associated with the prevalence of anti-
HBe-positive chronic hepatitis (Chu et al., 
2003). 
 However, it is important to note that this 
issue is not firmly established yet. This is 
because some other studies did not find 
such correlations between the genotypes 
and the prognosis of the liver diseases 
(McMahon et al., 2001; Sumi et al., 2003). 
In Malaysia, it is not known whether such 
correlation exists as no study has been  
undertaken to look into this question. 
 
Correlations of HBV genotypes with 
mutations affecting HBeAg production 
and HBe/ anti-HBe status 
 
Over the years of research on HBV 
genotypes, promoter mutation 
(A1762G1764→T1762A1764), precore 
stop codon mutations (TGG→TAG) and 
codon 15 variants (C1858/ T1858), various 
reports had been compiled on the 
correlations between these variables as 
well as the correlations between the 
genotypes with HBeAg/ anti-HBe status. 
 The core promoter mutations 
(A1762G1764→T1762A1764) had been 
observed to be more common in patients 
with HBV genotype C infections than 
genotype B (Lindh et al., 1999; Kao et al., 
2000b; Orito et al., 2001; Fang et al., 2002; 
Sakurai et al., 2004). However, in some 
studies, the correlations between HBV 
genotypes with core promoter mutations 
were not observed (Franca et al., 2004; 
Kidd-Ljunggren et al., 2004). This type of 
correlation was not observed in the 
Malaysian study undertaken by Lim et al. 
(2006) as well. 
 HBV genotype A had been associated 
with C1858 variants (codon 15) (Li et al., 
1993). Due to this, the cytosine (C) at 
nucleotide 1858 will not permit base-pairing 
to occur with adenine base (A) of 
nucleotide 1896 in genotype A. Thus, HBV 
genotype A has constraint in undergoing 
mutation from G to A at nucleotide 1896 to 
produce HBV strain with precore stop 
codon mutations, hence HBeAg-negative 
phenotype. This could partially explain for 
the high rate of chronic HBV infections in 
adult patients who are infected with this 
genotype, as observed in many European 
countries. This is also true in the case of 
genotype F (Kramvis and Kew, 1998). This 
is supported by the finding that patients 
infected with genotype A had higher 
HBeAg levels than those infected by 
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genotypes B and C, as discussed above 
(Kobayashi et al., 2002b). Genotypes B, C, 
D and E had been associated with the 
T1858 variants (codon 15). However 
infrequently, the C1858 variants could still 
be observed among patients infected with 
genotypes C and D (Kramvis and Kew, 
1998). This situation was observed in 
Malaysia where some C1858 variants were 
observed in some genotype C infected 
samples (Lim et al., 2006). 
 Despite these, some HBV strains of 
genotype A could still undergo the TAG 
mutation (codon 28). This is possible when 
the strain develops the C to T mutation at 
nucleotide 1858, thus preventing the 
destabilization of the pregenomic RNA 
stem loop structure which is essential for 
viral replication (Li et al., 1993; Blackberg 
and Kidd-Ljunggren, 2000). Due to the 
tendency of genotypes B, C, D and E to be 
associated with the T1858 variants (codon 
15), they are predisposed to TAG 
mutations (codon 28). Thus genotypes B, 
C, D and E were found to be associated 
more often with the TAG mutations (codon 
28) than genotype A (Huy et al., 2004). 
However, some other studies did not 
observe such correlations. Orito et al. 
(2001) observed no significant difference 
between the predispositions to the precore 
stop codon mutation development between 
genotypes B and C. This phenomenon was 
not observed as well in a later study by 
Kidd-Ljunggren et al. (2004) on samples 
from various geographic origins. The 
suggested correlation between genotype B 
with precore stop codon mutations seems 
to contradict to a study by Lim et al. (2006) 
on Malaysian samples infected with HBV. 
Even though large numbers of individuals 
infected with HBV genotypes B were found 
in their study, no precore stop codon 
mutations were detected among them. This 
could imply that other factors might play a 
role here, such as the geographic origin of 
the HBV strains. However, this does not 
seem to be the case as other studies 
conducted on HBV-infected Malaysian 
samples did observe some precore stop 
codon mutants even though their 
genotypes were unknown (Ton et al., 1996; 
2002; Yap et al., 2002). 
 Other than the associations of genotypes 
with the mutations, some studies had also 
observed the inequality in the distributions 
of HBeAg/ anti-HBe statuses between 
patients infected by different HBV 
genotypes. It was reported that patients 
infected by genotype B were more prone to 
be negative for HBeAg than in patients 
infected by genotypes C (Lindh et al., 
1999; Sakurai et al., 2004). This was 
supported by a study on HBV-infected 
patients in Thailand (Sugauchi et al., 
2002a). The reason behind these could be 
explained by the fact that patients infected 
by HBV genotype C experienced a longer 
delay in seroconversion to anti-HBe status 
(Lindh et al., 1999). Thus the consequence 
of this is that they will remain in the HBeAg 
positive status for a longer period of time. 
But this scenario was not observed among 
the Malaysian carriers infected with HBV 
genotypes B and C where no difference in 
the distributions of the HBeAg/anti-HBe 
statuses was observed (Lim et al., 2006). 
The collection timing of the HBV infected 
sera from the patients could be important 
with regards to the determination of 
HBeAg/ anti-HBe statuses of the patients 
as older patients tend to have 
seroconverted to anti-HBe. 
 
Associations of genotypic subtypes 
with other variables 
 
It was observed by Sugauchi et al. (2003) 
that the Bj and Ba subtypes correlated 
differently with the core promoter 
mutations. They found that the Ba subtype 
was more associated with the core 
promoter mutations than with the Bj 
subtype (33 % vs. 15 %) while the precore 
stop codon mutations occurred more 
frequently in the Bj subtype (50 % vs. 18 
%). Thus, the implication of these findings 
is that the correlation studies between 
genotypes and other factors such as 
disease prognosis or mutations associated 
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with HBeAg production is not that straight 
forward anymore. This is because when 
correlation studies between genotypes and 
other variables were performed, the 
proportions of the subtypes of one 
particular genotype could significantly 
influence the final outcome of the results. 
The final correlation results might be 
dependent upon the varying degree of 
proportions of the subtypes since it was 
shown that the association between the 
subtypes and other variables could be 
different. 
 Besides, a few studies had found that 
genotypic subtypes are significantly 
correlated with the prognosis of the liver 
disease as well. Studies in Japan revealed 
that the subtype Ba was more associated 
with severe liver disease as well as had 
higher tendency to develop HCC than in 
patients infected with the subtype Bj 
(Sugauchi et al., 2002b; 2003; Orito et al., 
2005). In Hawaii, it was observed that 
patients of Asian ethnicity (excluding 
Japanese) which were exclusively infected 
with the Ba subtype had higher rates of 
HBeAg positivity and core promoter 
mutations than the Bj subtype that was 
predominantly found to infect the Japanese 
(Orito et al. 2001; Sakurai et al., 2004). 
Another example of clinical difference 
resulted from different subtypes infections 
is shown in a study by Hayashi et al. 
(2007) in Japan where the genotypic 
subtypes of Ba and Cs were more 
frequently found in patients suffering from 
acute hepatitis B than in patients with 
chronic hepatitis B. 
 The varying proportions of the genotypic 
subtypes within the samples of studies 
could be the reason why contradictory 
results were reported when correlation 
studies between genotypes and other 
variables were performed. This includes a 
study carried out on a Malaysian sample 
population where no difference was ob-
served between genotypes B and C and 
the core promoter mutations. This is in 
contrast to what has been observed 
elsewhere (Lim et al., 2006). 
SUMMARY 
 
After many years of research on HBV, it is 
accepted that HBV is one of the causative 
agents for the development of acute and 
chronic hepatitis. Besides, infection by 
HBV is a risk factor for HCC. As the 
prevalence of HBV infection among the 
Malaysian population is relatively high, 
these infected individuals run the risk of 
developing the above conditions. Moreover 
a number of HBV variants exist which have 
diagnostic and clinical implications 
(Raimondo et al., 1991; Yotsumoto et al., 
1992; Okamoto et al., 1994; Sato et al., 
1995; Lindh et al., 1996; Kao et al., 2000a). 
 Mutations in the HBV genome can affect 
the expression of HBeAg. Examples of 
these are the core promoter dual mutations 
(A1762G1764→T1762A1764), the codon 
15 variants (C1858/ T1858) and the 
precore stop codon mutations (TGG→ 
TAG). The HBV can be categorized into 
eight genotypes (A to H) as well as 
genotypic subtypes and recombinants. 
These could differ in their affiliations with 
the mutations and with disease prognosis. 
Although vaccination program has been 
introduced into Malaysia, a substantial 
proportion of the Malaysian population is 
still afflicted with HBV infections though the 
prevalence has decreased. The number of 
studies undertaken in Malaysia on this 
virus is still considerably low. Therefore it is 
important that more studies on HBV in 
Malaysia are conducted so as to better 
understand the epidemiology, morpho-
genesis and pathogenesis behavior of the 
virus in relation to the Malaysian po-
pulation. One particular area of HBV 
research that is still lacking is the study on 
the genotypic subtypes which is getting 
more important as it has been shown to be 
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